Lucid Diagnostics (LUCD) CFO granted 470,000 restricted shares vesting in 2029

Rhea-AI Filing Summary

Lucid Diagnostics Inc. reported that Chief Financial Officer Dennis M. McGrath acquired 470,000 shares of common stock through a restricted stock grant at a price of $0.00 per share. These shares vest in a single installment on May 20, 2029 and are subject to forfeiture if the required service period is not completed. Following this award, McGrath directly holds 1,813,569 shares of Lucid Diagnostics common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider MCGRATH DENNIS M

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common stock	470,000	$0.00	--

Holdings After Transaction: Common stock — 1,813,569 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MCGRATH DENNIS M

(Last) (First) (Middle)

360 MADISON AVENUE, 25TH FLOOR

(Street)

NEW YORK NY 10017

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Lucid Diagnostics Inc. [ LUCD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common stock	02/20/2026		A		470,000(1)	A	$0	1,813,569	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with a single vesting date of May 20, 2029. Such restricted stock is subject to forfeiture if the requisite service period is not completed.

	/s/ Michael A. Gordon, by power of attorney	02/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Lucid Diagnostics (LUCD) disclose for its CFO?

Lucid Diagnostics reported that CFO Dennis M. McGrath received a grant of 470,000 shares of restricted common stock. The award was made at a price of $0.00 per share and increases his directly held stake to 1,813,569 shares of Lucid Diagnostics common stock.

What type of shares did the Lucid Diagnostics (LUCD) CFO receive?

The CFO received restricted common stock under Lucid Diagnostics’ 2018 Equity Plan. These are time-based equity awards that do not fully belong to him unless vesting conditions are met, aligning his compensation with long-term company performance and continued service.

When do the Lucid Diagnostics (LUCD) CFO’s restricted shares vest?

The 470,000 restricted shares granted to the CFO vest on a single date of May 20, 2029. Until that vesting date, the award remains subject to service-based conditions and can be forfeited if he does not complete the required service period.

Are the Lucid Diagnostics (LUCD) CFO’s restricted shares subject to forfeiture?

Yes, the restricted stock grant is explicitly subject to forfeiture. If the CFO does not complete the requisite service period through the May 20, 2029 vesting date, some or all of the 470,000 restricted shares may be forfeited under the equity plan terms.

How many Lucid Diagnostics (LUCD) shares does the CFO own after this grant?

After receiving the 470,000-share restricted stock grant, the CFO directly holds a total of 1,813,569 shares of Lucid Diagnostics common stock. This total reflects his beneficial ownership immediately following the reported equity award acquisition transaction.

Under which plan were the Lucid Diagnostics (LUCD) restricted shares granted?

The restricted shares were granted under Lucid Diagnostics’ 2018 Equity Plan. This plan governs equity-based compensation, including restricted stock awards, and sets the vesting schedule, service requirements, and forfeiture provisions that apply to the CFO’s 470,000-share grant.